Dear Colleague:

As you are aware, Sanofi Pasteur is experiencing a manufacturing delay that will reduce the supply of Pentacel® (DTaP-IPV/Hib vaccine) through the first half of 2016, and possibly longer. As a result, the New York City Vaccines for Children (VFC) program vaccine allocation has been substantially reduced, and limitations have been placed on the amount of Pentacel that can be ordered.

Because other vaccines are available, little to no impact to routine childhood immunization is anticipated. Providers may use other combination products (DTaP-IPV-HepB [Pediarix®, GSK] and DTaP-IPV [Kinrix®, GSK]), or individual products (DTaP [Daptacel®, Sanofi Pasteur; Infanrix®, GSK], IPV [Ipil®, Sanofi Pasteur], and Hib [PedvaxHIB®, Merck; ActHIB®, Sanofi Pasteur; and Hiberix®, GSK]) as alternatives. At this time, the VFC program anticipates having adequate supply of these other vaccines. Please note that by using such products, all children will be able to be fully immunized on time.

Please see the attached letter from Sanofi Pasteur and guidance from the Centers for Disease Control and Prevention. If you have questions or require additional information, please contact your Sanofi Pasteur Vaccine Specialist or a Customer Account Representative at 1-800-VACCINE (1-800-822-2463). For questions about VFC orders, please contact the VFC program at 347-396-2405 or email us at nycimmunize@health.nyc.gov.

We will continue to keep you informed as we receive additional information. Updates will also be posted to the VFC ordering screen in the Online Citywide Immunization Registry (CIR). Thank you.

Sincerely,

Jane R. Zucker, MD, MSc